SER - NYSE
Serina Therapeutics, Inc.
$5.00
+0.0000%Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
At a Glance
Live SnapshotSerina Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Serina Therapeutics, Inc. Income Statement
SER • NYSE
| Serina Therapeutics, Inc. Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
56K | 3.2M | 500K | 3M | 54K | 1.7M | 1.4M | 1.4M | 1.7M | |
GROSS PROFIT | |||||||||
(194K) | (90K) | (145K) | (150K) | (1.3M) | (998.5K) | (841K) | (685K) | (911K) | |
-138K | 3.1M | 355K | -110K | -1.2M | 729.5K | 555K | 719K | 755K | |
OPERATING INCOME | |||||||||
(17.1M) | (6.2M) | (6.9M) | (4.7M) | (9.2M) | (13.3M) | (11M) | (9.1M) | (13.5M) | |
(9.4M) | (3.9M) | (1.3M) | (6.7M) | (5.6M) | (7.9M) | (5.6M) | (3.9M) | (5.6M) | |
(7.5M) | (2.4M) | (893K) | (1.3M) | (3.6M) | (5.3M) | (5.4M) | (5.3M) | (7.9M) | |
-17M | -3.1M | -2.3M | -1.6M | -10.4M | -12.6M | -10.4M | -8.4M | -12.7M | |
PRE-TAX INCOME | |||||||||
(526K) | (558K) | (15.9K) | (3.1K) | (404K) | (0.0) | (0.0) | (12K) | (25K) | |
-526K | -558K | -14.1K | 7.8K | -404K | 0.0 | 0.0 | 0.0 | 0.0 | |
(194K) | -90K | (4.7M) | -3.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
5.9M | 8.4M | -411.7K | 366.8K | 8K | 323K | 2.7M | 1.8M | -4.6M | |
-11.1M | 5.3M | -2.7M | -1.3M | -10.4M | -12.2M | -7.7M | -6.6M | -17.4M | |
NET INCOME | |||||||||
(0.0) | -8K | (0.0) | (0.0) | (0.0) | (148K) | (0.0) | -57K | (0.0) | |
-11.1M | 5.3M | -2.7M | -1.3M | -10.9M | -12.2M | -7.5M | -6.6M | -15.5M |
SEC Filings
SER - Filing history and reports
No SEC filings available for SER
Related Guides
Continue your SER research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.